INDV Indivior Pharmaceuticals, Inc.

Q3 2025 10-Q

Filed: Oct 30, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Indivior Pharmaceuticals, Inc. (INDV) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• No revenue or profitability details disclosed in this MD&A excerpt
• No segment or product line performance data provided

+2 more insights

Risk Factors

• New regulatory risk from 2025 OBBBA law, potentially limiting patient eligibility and treatment access for OUD starting 2027-2028
• Material update: CMS finalized Marketplace Integrity and Affordability Regulation in June 2025, changing ACA open enrollment and premium tax credit eligibility

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$313M

Net Income

$43M

Gross Margin

73.5%

Operating Margin

13.7%

Net Margin

13.7%

ROE

-20.8%

Total Assets

$1.4B

Source: XBRL data from Indivior Pharmaceuticals, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Indivior Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.